NQO1
Basic information
Region (hg38): 16:69706996-69726668
Previous symbols: [ "NMOR1", "DIA4" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the NQO1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 107 | 108 | ||||
missense | 109 | 116 | ||||
nonsense | 1 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 2 | 2 | ||||
non coding | 4 | |||||
Total | 0 | 2 | 110 | 115 | 2 |
Variants in NQO1
This is a list of pathogenic ClinVar variants found in the NQO1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
16-69710977-C-T | not specified | Likely benign (Apr 07, 2022) | ||
16-69710984-T-C | not specified | Uncertain significance (May 05, 2023) | ||
16-69710985-A-T | not specified | Likely benign (Mar 01, 2024) | ||
16-69710986-G-T | not specified | Uncertain significance (Apr 07, 2024) | ||
16-69710992-A-T | not specified | Uncertain significance (Jun 08, 2023) | ||
16-69710994-C-G | not specified | Benign/Likely benign (Sep 20, 2022) | ||
16-69711000-G-A | not specified | Likely benign (Mar 29, 2022) | ||
16-69711001-T-A | not specified | Uncertain significance (Mar 30, 2022) | ||
16-69711002-C-T | not specified | Uncertain significance (Jun 23, 2022) | ||
16-69711003-A-G | not specified | Likely benign (Mar 04, 2021) | ||
16-69711006-T-G | not specified | Likely benign (Apr 15, 2021) | ||
16-69711009-G-A | not specified | Likely benign (Jan 04, 2023) | ||
16-69711012-G-A | not specified | Likely benign (May 03, 2021) | ||
16-69711012-G-T | not specified | Likely benign (Sep 03, 2022) | ||
16-69711013-G-C | not specified | Uncertain significance (Mar 07, 2022) | ||
16-69711014-A-T | not specified | Uncertain significance (Jun 23, 2022) | ||
16-69711016-T-C | not specified | Uncertain significance (Sep 12, 2023) | ||
16-69711018-G-C | not specified | Likely benign (Dec 23, 2022) | ||
16-69711021-C-A | not specified | Uncertain significance (Nov 02, 2023) | ||
16-69711024-G-A | NQO1-related disorder • not specified | Likely benign (Feb 23, 2022) | ||
16-69711026-G-A | not specified | Uncertain significance (Jul 31, 2021) | ||
16-69711027-A-G | not specified | Likely benign (Jun 30, 2019) | ||
16-69711028-T-C | not specified | Uncertain significance (Oct 20, 2022) | ||
16-69711029-G-A | not specified | Uncertain significance (May 10, 2024) | ||
16-69711032-C-T | not specified | Uncertain significance (May 31, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
NQO1 | protein_coding | protein_coding | ENST00000320623 | 6 | 19956 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.19e-9 | 0.101 | 124869 | 12 | 866 | 125747 | 0.00350 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.28 | 106 | 150 | 0.705 | 0.00000768 | 1803 |
Missense in Polyphen | 35 | 58.312 | 0.60022 | 687 | ||
Synonymous | -0.0322 | 58 | 57.7 | 1.01 | 0.00000338 | 516 |
Loss of Function | 0.113 | 14 | 14.5 | 0.968 | 7.88e-7 | 157 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0414 | 0.0412 |
Ashkenazi Jewish | 0.000199 | 0.000198 |
East Asian | 0.000326 | 0.000326 |
Finnish | 0.000739 | 0.000739 |
European (Non-Finnish) | 0.000810 | 0.000809 |
Middle Eastern | 0.000326 | 0.000326 |
South Asian | 0.000261 | 0.000261 |
Other | 0.00310 | 0.00310 |
dbNSFP
Source:
- Function
- FUNCTION: The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinons involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis.;
- Pathway
- Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Doxorubicin Pathway (Cancer Cell), Pharmacodynamics;Hepatocellular carcinoma - Homo sapiens (human);Fluid shear stress and atherosclerosis - Homo sapiens (human);Doxorubicin Pathway, Pharmacokinetics;Pathways in cancer - Homo sapiens (human);Phenytoin Pathway, Pharmacokinetics;Platinum Pathway, Pharmacokinetics/Pharmacodynamics;Phenytoin (Antiarrhythmic) Action Pathway;Doxorubicin Metabolism Pathway;Vitamin K Metabolism;Dopamine metabolism;Aryl Hydrocarbon Receptor;Apoptosis-related network due to altered Notch3 in ovarian cancer;Aryl Hydrocarbon Receptor Pathway;Nuclear Receptors Meta-Pathway;NRF2 pathway;Transcriptional activation by NRF2;Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling;Simplified Interaction Map Between LOXL4 and Oxidative Stress Pathway;Benzene metabolism;Oxidative Stress;Estrogen metabolism;Regulation of ornithine decarboxylase (ODC);Metabolism of polyamines;Metabolism of amino acids and derivatives;Metabolism;Validated transcriptional targets of TAp63 isoforms
(Consensus)
Recessive Scores
- pRec
- 0.755
Intolerance Scores
- loftool
- 0.989
- rvis_EVS
- 0.55
- rvis_percentile_EVS
- 81.38
Haploinsufficiency Scores
- pHI
- 0.130
- hipred
- Y
- hipred_score
- 0.575
- ghis
- 0.408
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.989
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | High |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Nqo1
- Phenotype
- neoplasm; homeostasis/metabolism phenotype; cellular phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan);
Gene ontology
- Biological process
- regulation of cellular amino acid metabolic process;xenobiotic metabolic process;nitric oxide biosynthetic process;synaptic transmission, cholinergic;aging;response to nutrient;response to toxic substance;removal of superoxide radicals;electron transport chain;response to estradiol;negative regulation of apoptotic process;negative regulation of catalytic activity;positive regulation of neuron apoptotic process;response to ethanol;response to electrical stimulus;cellular response to hydrogen peroxide;cellular response to metal ion;response to nitrogen compound;response to hydrogen sulfide
- Cellular component
- cytoplasm;cytosol;dendrite;neuronal cell body
- Molecular function
- RNA binding;NAD(P)H dehydrogenase (quinone) activity;cytochrome-b5 reductase activity, acting on NAD(P)H;superoxide dismutase activity;protein binding;electron transfer activity;oxidoreductase activity;identical protein binding